The Progress and Situation of Extended Continental Shelf Delineation Worldwide

方银霞，国家海洋局第二海洋研究所专属经济区与大陆架研究中心研究员。尹洁，国家海洋局第二海洋研究所专属经济区与大陆架研究中心助理研究员。唐勇，国家海洋局第二海洋研究所专属经济区与大陆架研究中心研究员。李金蓉，国家海洋信息中心，助理研究员。【中文摘要】：自2001年俄罗斯率先提交划定其200海里以外大陆架外部界限的划界案以来已经15年，截至2016年6月30日，大陆架界限委员会收到的划界案总数达81个，完成审议并通过委员会建议的划界案有24个。本文系统介绍了全球外大陆架划界案提交情况、委员会对划界案的处理模式以及审议时重点关注的问题等，并从科学和法律两个角度分析了当前外大陆架划界实践的特点与未来发展趋势。因此，本文建议，我们应加大相关科学技术和法理问题研究，及时总结大陆架制度理论与实践的最新发展，以便为我国今后外大陆架划界和积极应对侵害我国海洋权益的他国划界主张提供参考和借鉴。 【Abstract】In 2001, Russia made the first submission, containing proposed outer limits of its continental shelf beyond 200 nautical miles (nm) from the base-lines from which the breadth of the territorial sea is measured, to the Commission on the Limits of the Continental Shelf (CLCS). As of 30 June 2016, the CLCS had received 81 submissions and had reviewed and released recommendations on 24 of them. After systematically outlining the situation of the submissions that have been, are being, or will be filed by States, the modes that CLCS adopts to treat submissions, and the primary issues that the CLCS examines during its consideration of submissions, this paper explores, from both scientific and legal perspectives, the features of current practice with respect to extended continental shelf delineation, as well as its development tendency.In this context, this paper suggests that greater efforts should be invested in the study of relevant scientific, technical and legal issues, and the latest developments regarding the theories and practice of the continental shelf regime should be learned and summarized in a timely manner, which could be used for reference by China in the delineation of its extended continental shelf, or when China's maritime rights and interests are undermined by other States' claims of continental shelf.本文获海洋公益性行业科研专项经费资助项目（编号：201205003）和国家自然科学基金项目（编号：41476048 和41401142）资助

Physiological Ischemic Training Promotes Brain Collateral Formation and Improves Functions in Patients with Acute Cerebral Infarction

Objectives: To observe the effectiveness and mechanisms of physiological ischemic training (PIT) on brain cerebral collateral formation and functional recovery in patients with acute cerebral infarction.Methods: 20 eligible patients with acute cerebral infarction were randomly assigned to either PIT group (n = 10) or Control group (n = 10). Both groups received 4 weeks of routine rehabilitation therapy, while an additional session of PIT, which consisted of 10 times of maximal voluntary isometric handgrip for 1 min followed by 1 min rest, was prescribed for patients in the PIT groups. Each patient was trained with four sections a day and 5 days a week for 4 weeks. The Fugl-Meyer Assessment (FMA), the Modified Barthel Index (MBI), and the short-form 36-item health survey questionnaire (SF-36) were applied for the evaluation of motor impairment, activity of daily living, and quality of life at the baseline and endpoint. MRI was applied to detect the collateral formation in the brain. The concentration of vascular endothelial growth factor (VEGF) and endothelial progenitor cells (EPCs) number in plasma were also tested at the endpoint.Results: Demographic data were consistent between experimental groups. At the endpoint, the scores of the FMA, MBI, and SF-36 were significantly higher than that at baseline. As compared to the Control group, the score of FMA and SF-36 in PIT group was significantly higher, while no significant difference was detected between groups in terms of MBI. Both groups had significantly higher cerebral blood flow (CBF) level at endpoint as compared to that at baseline. Moreover, the CBF level was even higher in the PIT group as compared to that in the Control group after 4 weeks of training. The same situations were also found in the plasma VEGF and EPCs assessment. In addition, positive correlations were found between FMA score and CBF level (r = 0.686, p < 0.01), CBF level and VEGF concentration (r = 0.675, p < 0.01), and VEGF concentration and EPC number (r = 0.722, p < 0.01).Conclusion: PIT may be effective in increasing the expression of VEGF and recruitment of EPCs and in turn promote the formation of brain collateral circulation. The positive correlations may demonstrate a potential association between biological and functional parameters, and PIT may be able to improve the motor function, activity of daily living, and quality of life in patients with stroke.Interdisciplinary Division of Biomedical Engineerin

The value of interleukin-27 for differentiating tuberculous pleural effusion from Mycoplasma pneumoniae pneumonic effusion in children

ObjectivesThe early diagnosis of tuberculous pleural effusion (TPE) is challenging due to the difficulty of isolating Mycobacterium tuberculosis, and pleural biomarkers are an optional choice. Recent studies showed that interleukin-27 (IL-27) appears to be a new accurate biomarker for TPE in adults and no related studies were reported in children. In this study, we aimed to evaluate the potential value of IL-27 in pediatric tuberculous pleurisy by detecting its levels in pleural fluid and serum.MethodsA total of 48 children with TPE and 64 children with severe Mycoplasma pneumoniae (MP) pneumonic effusion (SMPPE) were enrolled in this study. IL-27 concentrations were measured in serum and pleural fluid. The diagnostic yield of IL-27 was evaluated using receiver operating characteristic (ROC) curves.ResultsThe level of p-IL-27 in TPE showed statistically no significant difference when compared with SMPPE (p &gt; 0.05). However, pleural fluid IL-27 (p-IL-27) / serum IL-27 (s-IL-27) ratio in TPE were significantly much higher than those in SMPPE (p &lt; 0.05). By the analysis of the ROC curves, the diagnostic sensitivity and specificity of the p-IL-27/s-IL-27 ratio were 100% and 48.44%, respectively (cutoff value of 1.0280). The area under the ROC curve for p-IL-27/s-IL-27 was 0.7295.ConclusionPleural fluid IL-27 alone was not accurate in distinguishing pediatric TPE from SMPPE, which was different from the diagnostic value of IL-27 in adult studies due to the different disease spectra between children and adults. Our results implied that the p-IL-27/s-IL-27 ratio had a potential value in distinguishing TPE from SMPPE. However, the specificity of IL-27 was relatively lower and it is necessary to find a more specific marker in tuberculous pleurisy of children

Hepcidin and iron metabolism in preterm infants

Background: Iron deficiency (ID) and ID anemia are widespread in low-income countries, particularly among preterm infants. Hepcidin is a key regulator of iron metabolism, which offers the possibility of new solutions to diagnose ID in premature infants. Objective: To explore the relationship between iron metabolism and hepcidin in premature infants. Materials and methods: The study involved 81 preterm infants between 28+1 and 36+6 who underwent iron status indicators and hepcidin testing at 6 months of corrected gestational age. The preterm infants were divided into two groups based on iron status indicators: ID and no ID. Results: Serum hepcidin was lower for premature infants with ID compared to those without ID (log10hepcidin, 1.18 ± 0.44 vs 1.49 ± 0.37, p = 0.002). A single-variate linear regression model was used to explore the correlation between hepcidin and other indicators of iron metabolism. A strongly positive relationship was observed between hepcidin levels and ferritin levels (p < 0.001) in the correlation analysis. Conclusions: Hepcidin can be used as an efficient indicator of iron storage and a promising indicator for the early diagnosis of ID in premature infants

Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion

The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied. In a multicenter trial in China, we enrolled patients with ischemic stroke without occlusion of large or medium-sized vessels and with a National Institutes of Health Stroke Scale score of 5 or more and at least one moderately to severely weak limb. Eligible patients had any of four clinical presentations: ineligible for thrombolysis or thrombectomy and within 24 hours after the patient was last known to be well; progression of stroke symptoms 24 to 96 hours after onset; early neurologic deterioration after thrombolysis; or thrombolysis with no improvement at 4 to 24 hours. Patients were assigned to receive intravenous tirofiban (plus oral placebo) or oral aspirin (100 mg per day, plus intravenous placebo) for 2 days; all patients then received oral aspirin until day 90. The primary efficacy end point was an excellent outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. Secondary end points included functional independence at 90 days and a quality-of-life score. The primary safety end points were death and symptomatic intracranial hemorrhage. A total of 606 patients were assigned to the tirofiban group and 571 to the aspirin group. Most patients had small infarctions that were presumed to be atherosclerotic. The percentage of patients with a score of 0 or 1 on the modified Rankin scale at 90 days was 29.1% with tirofiban and 22.2% with aspirin (adjusted risk ratio, 1.26; 95% confidence interval, 1.04 to 1.53, P = 0.02). Results for secondary end points were generally not consistent with the results of the primary analysis. Mortality was similar in the two groups. The incidence of symptomatic intracranial hemorrhage was 1.0% in the tirofiban group and 0% in the aspirin group. In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

Importance It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy. Objective To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO. Design, Setting, and Participants This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.InterventionsEligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy. Main Outcomes and Measures The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours. Results Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo. Conclusions and Relevance Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.Trial RegistrationChiCTR.org.cn Identifier: ChiCTR210005172

Formation and types of natural gas reservoirs of the Tangyuan fault depression in Yi-Shu graben

Based on drilling, logging and geochemical data from 32 wells, the depositional and tectonic evolution of the Tangyuan fault depression were studied and the gas accumulation conditions and gas reservoir types were analyzed. Based on interpretation of 2D and 3D seismic data, a structure map of each layer was plotted and the trap types developed in various structural layers were found and confirmed. The source rock of the Tangyuan fault depression was mainly developed in the Cretaceous and in the Eogene Wuyun Formation, Xin'ancun Formation, Dalianhe Formation Member 1 and Baoquanling Formation Member 1. The reservoirs are of similar age and include the Eogene Wuyun Formation, Xin'ancun Formation, Dalianhe Member 2 and Baoquanling Member 2. The caprock was developed in the Dalianhe and Baoquanling Member 1. There are three types of source-reservoir-caprock assemblages present which include self-generating & self-preserving, lower-generating & upper-preserving and new-bed-generating & old-bed-preserving. Drilling has demonstrated that there are two types of gas reservoirs, a composition lithologic-structural gas reservoir and a lithologic gas reservoir. With reference to the seismic data and known reservoir data in adjacent areas, it is estimated that there may also be structural gas reservoirs and stratigraphic gas reservoirs. Key words: Reservoir formation conditions, gas reservoir type, structure evaluation, Tangyuan fault depressio

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall survival (OS) and is associated with lower hematologic toxicity. Accordingly, S-1 is a convenient oral alternative treatment for advanced PDAC. This study was aimed at comparing the efficacy and safety of gemcitabine plus S-1 (GS) vs. GnP as first-line chemotherapy for advanced PDAC. Methods: Patients with advanced PDAC who received first-line GS or GnP at the Peking Union Medical College Hospital between March 2011 and November 2022 were evaluated. Results: A total of 300 patients were assessed, of whom 84 received GS and 216 received GnP. The chemotherapy completion rate was higher with GS than GnP (50.0% vs. 30.3%, P = 0.0028). The objective response rate (ORR) was slightly higher (14.3% vs. 9.7%, P = 0.35), and the median OS was significantly longer (17.9 months vs. 13.3 months, P = 0.0078), in the GS group than the GnP group. However, the median progression-free survival (PFS) did not significantly differ between groups. Leukopenia risk was significantly lower in the GS group than the GnP group (14.9% vs. 28.1%, P = 0.049). Conclusions: As first-line chemotherapy for advanced PDAC, the GS regimen led to a significantly longer OS than the GnP regimen. The PFS, ORR, and incidence of severe adverse events were comparable between the GS and GnP groups